SCHEMBL765425

SCHEMBL765425

CC(=O)Nc1c[c]nc(C)n1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 2/20 0.39
LMNA P02545 1/20 0.39
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
ADORA3 P0DMS8 8/20 0.37
PIK3CG P48736 1/20 0.37
PTK2 Q05397 1/20 0.36
ADORA1 P30542 2/20 0.35
ADORA2B P29275 2/20 0.35
ADORA2A P29274 2/20 0.35
MAPK8 P45983 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
GLS O94925 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL750983 0.80 HPGD (0.49) L3MBTL1LMNAADORA3ADORA1ADORA2B
SCHEMBL751121 0.77 PARP1 (0.39) L3MBTL1ADORA1ADORA2A
SCHEMBL752561 0.76 ABL1 (0.39) KDM4ETDP1CYP1A2CYP2C19
SCHEMBL15322822 0.74 L3MBTL1 (0.48) L3MBTL1KDM4ELMNAHSP90AA1HSP90AB1
SCHEMBL753002 0.74 KDM4E (0.43) KDM4ETDP1
SCHEMBL751783 0.73 ALDH1A1 (0.47) KDM4ELMNACYP2C9CYP2C19
SCHEMBL7168455 0.68 L3MBTL1 (0.57) L3MBTL1KDM4ELMNAHSP90AA1HSP90AB1
SCHEMBL20068960 0.68 SORT1 (0.54) L3MBTL1KDM4ELMNAHSP90AA1HSP90AB1
SCHEMBL115774 0.67 NPC1 (0.48) L3MBTL1ADORA3PIK3CGPTK2ADORA1
SCHEMBL4418275 0.66 GLS (0.58) L3MBTL1KDM4ELMNAHSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP disclosed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD L3MBTL1 4014/4885KDM4E 1665/4885LMNA 3090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.